CRVS - Corvus Pharmaceuticals, Inc.
NasdaqGM - NasdaqGM Real-time price. Currency in USD
At close: 04:00PM EDT
After hours:
Stock chart is not supported by your current browser
| Previous close | 2.6000 |
| Open | 2.7500 |
| Bid | 2.9300 x 900 |
| Ask | 3.1900 x 1200 |
| Day's range | 2.7450 - 3.2400 |
| 52-week range | 0.6070 - 3.7000 |
| Volume | |
| Avg. volume | 773,667 |
| Market cap | 143.897M |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7800 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.88 |
ZacksIs Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.
ZacksCorvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.
ZacksCorvus (CRVS) Moves to Buy: Rationale Behind the Upgrade
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).